Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Qiuyun Fang, Fei Li, Aijun Liao, Qingsong Yin, Lin Yang, Lianrong Xu, Junjie Ma, Junqing Xu, Hao Zhang, Jieyu Wang, Shaowei Qiu, Bingcheng LIU, Yingchang Mi, Jianxiang Wang, Hui Wei

Blood (2025) 146 (Supplement 1): 650.

https://doi.org/10.1182/blood-2025-650

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 91.

https://doi.org/10.1182/blood-2025-91

Published: 2025

Journal Articles

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Qun Li, Xiaojing Yan, Jian-Qing Mi, Aijun Liao, Bingzong Li, Hui-Han Wang, Huili Cai, Yafei Wang, Li Cai, Yu Hu, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2025-3984

Published: 2025

Journal Articles

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Blood (2025) 146 (Supplement 1): 7583.

https://doi.org/10.1182/blood-2025-7583

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China

Shu Zhao, Wenhui Zhao, Lintao Bi, Libo Jiang, Chun Zhang, Xiaoling Li, Wei WANG, Xiaojing Xing, Hong Luo, Aijun Liao, danhong li, Ruiyang Sun, Qing-Yuan Zhang

Blood (2025) 146 (Supplement 1): 7211.

https://doi.org/10.1182/blood-2025-7211

Published: 2025

Journal Articles

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Menghan Liu, Xiaoqi Qin, Weiwei Tian, Yuechen Zhang, Yanru Zhang, Lefu Huang, Wenjing Li, Jingrong Wang, Yanping Ma, Liping Su, Yan Yan, Aijun Liao, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2025-2280

Published: 2025

Journal Articles

Early dflc response for predicting complete hematological response in patients with AL amyloidosis: A multi-center prospective observational study

Yang Liu, Xianghuang Huang, Huasheng Liu, Liru Wang, Yanqiu Zhao, Yini Wang, Yuping Zhong, Aijun Liao, Aili Zhai, Jinzhou Guo, Huinan Jiang, Xiaojun Huang, Jin Lu

Blood (2025) 146 (Supplement 1): 7496.

https://doi.org/10.1182/blood-2025-7496

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Ling Qin, Yuping Zhong, Dongping Huang, Haitang Xie, Xin Du, Aijun Liao, Hongli Zhang, Shengli (Charles) Cai, Jin Lu

Blood (2024) 144 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2024-202871

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

Huinan Jiang, Xianming He, Qing Leng, Miao Miao, Ming Zhang, Yingchun Li, Guojun Zhang, Jia Li, Rong Zhang, Ying Lv, Zhuogang Liu, Fei Tian, Rong Li, Wenxia Liu, Rui Zhang, Xiaohong Wang, Aijun Liao

Blood (2024) 144 (Supplement 1): 7081.

https://doi.org/10.1182/blood-2024-201906

Published: 2024

Journal Articles

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

Yiming Wu, Meiling Jin, Mike Fernandez, Kevyn Hart, Aijun Liao, Stacey M. Fernandes, Tinisha McDonald, Lucy Ghoda, Daniel Roeth, Markus Kalkum, Raju Pillai, Jianjun Chen, Jennifer R Brown, Alexey V. Danilov, Steven T. Rosen, Tanya Siddiqi, Lili Wang

Blood (2021) 138 (Supplement 1): 499.

https://doi.org/10.1182/blood-2021-149691

Published: 2021

Journal Articles

R-Loop Associated Mitotic Stress Confers Vulnerabilities in Splicing Factor Mutant Leukemia

Martina Cusan, Meiling Jin, Bo Zhang, Mike Fernandez, Aijun Liao, Lu Yang, Yiming Wu, Prajish Iyer, Kevyn Hart, Catherine Gutierrez, Jeremy Stark, Teresa V. Bowman, Catherine J. Wu, Ren-Jang Lin, Lili Wang

Blood (2021) 138 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2021-151298

Published: 2021

Journal Articles

Integrative Transcriptome and Quantitative Proteome Analyses Identify METTL3 As a Key Regulator for Aberrant RNA Processing in Chronic Lymphocytic Leukemia

Yiming Wu, PhD, Meiling Jin, PhD, Kevyn Hart, BS, Aijun Liao, MD PhD, Stacey M. Fernandes, BS, Tinisha McDonald, BS, Lucy Brown, PhD, Daniel Roeth, PhD, Markus Kalkum, PhD, Raju Pillai, MD, Jianjun Chen, PhD, Jennifer R Brown, MD PhD, Steven T. Rosen, MD, Tanya Siddiqi, MD, Lili Wang, MDPhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-139841

Published: 2020

Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Blood (2019) 134 (Supplement_1): 5493.

https://doi.org/10.1182/blood-2019-125447

Published: 2019

Journal Articles

Evaluation of Chinese People Quality of Life Who Suffer From Hematologic Diseases

Rong Hu, Ying Yang, Bin Wu, Ke Zhu, Miao Miao, Aijun Liao, Wei Yang, Zhuogang Liu

Blood (2011) 118 (21): 4776.

https://doi.org/10.1182/blood.V118.21.4776.4776

Published: 2011

Journal Articles

FTY720 Induces Apoptosis and Autophagy in Multiple Myeloma Cells

Aijun Liao, Rong Hu, Qihui Zhao, Huihan Wang, Yingchun Li, Kun Yao, Rong Zhang, Wei Yang, Zhuogang Liu

Blood (2011) 118 (21): 5103.

https://doi.org/10.1182/blood.V118.21.5103.5103

Published: 2011

Journal Articles

Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia

Blood (2011) 118 (10): 2793–2800.

https://doi.org/10.1182/blood-2011-01-331447

Published: 2011

Includes: Supplemental data

Journal Articles

Therapeutic Efficacy of FTY720 In a Rat Model of LGL Leukemia

Xin Liu, Aijun Liao, Hong-Gang Wang, Dhimant Desai, Shantu Amin, Thomas P. Loughran, Jr., MD

Blood (2010) 116 (21): 776.

https://doi.org/10.1182/blood.V116.21.776.776

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Early dflc response for predicting complete hematological response in patients with AL amyloidosis: A multi-center prospective observational study

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

R-Loop Associated Mitotic Stress Confers Vulnerabilities in Splicing Factor Mutant Leukemia

Integrative Transcriptome and Quantitative Proteome Analyses Identify METTL3 As a Key Regulator for Aberrant RNA Processing in Chronic Lymphocytic Leukemia

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Evaluation of Chinese People Quality of Life Who Suffer From Hematologic Diseases

FTY720 Induces Apoptosis and Autophagy in Multiple Myeloma Cells

Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia

Therapeutic Efficacy of FTY720 In a Rat Model of LGL Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only